Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells

GLIA

Volumn 40, Issue 1, 2002, Pages 44-54

  Tentori, Lucio ^a   Portarena, Ilaria ^a   Torino, Francesco ^a   Scerrati, Massimo ^b   Navarra, Pierluigi ^b   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cell cycle; Drug resistance; Glioblastoma multiforme; Methylating agent; Telomerase

Indexed keywords

3 AMINOBENZAMIDE; 3-AMINOBENZAMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CDC25C PROTEIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; DACARBAZINE; DRUG DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PROTEIN; PROTEIN KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TEMOZOLOMIDE;

ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL CYCLE G2 PHASE; DNA REPAIR; DOWN REGULATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; GLIOBLASTOMA; GLIOMA; HUMAN; METABOLISM; MITOSIS; UPREGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BRAIN NEOPLASMS; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; DACARBAZINE; DNA REPAIR; DOWN-REGULATION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; G2 PHASE; GLIOBLASTOMA; GLIOMA; HUMANS; MITOSIS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0036793612     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10113     Document Type: Article

References (56)

1. Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Parhar P, Miller DC, Newcomb EW. 2001. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 61:2124-2128.
2. Amariglio N, Friedman E, Mor O, Stiebel H, Phelan C, Collins P, Nordenskjold M, Brok-Simoni F, Rechavi G. 1995. Analysis of microsatellite repeats in pediatric brain tumors. Cancer Genet Cytogenet 84:56-59.
3. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW. 1995. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly-(ADP-ribose) polymerase inhibitors. Br J Cancer 72:849-856.
4. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH. 1997. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488.
5. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. 1998. Potentiation of anti-cancer agent cytotoxicity by the potent poly-(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78:1269-1277.
6. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. 2001. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266.
7. Burger PC, Vogel FS, Green SB, Strike TA. 1985. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 56:1106-1111.
8. Cleaver JE. 1984. Differential toxicity of 3-aminobenzamide to wild-type and 6-thioguanine-resistant Chinese hamster cells by interference with pathways of purine biosynthesis. Mutat Res 131:123-127.
9. Dams E, Van de Kelft EJ, Martin JJ, Verlooy J, Willems PJ. 1995. Instability of microsatellites in human gliomas. Cancer Res 55:1547-1549.
10. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. 1998. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
11. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. 1988. Grading of astrocytomas: a simple and reproducible method. Cancer 62:2152-2165.
12. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. 2000. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6:2860-2867.
13. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ. 1997. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093-1100.
14. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, Graziani G. 1997. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3:579-585.
15. Faraoni I, Graziani G, Turriziani M, Masci G, Mezzetti M, Testori A, Veronesi U, Bonmassar E. 1999. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples. Lab Invest 79:993-1005.
16. Faraoni I, Bonmassar E, Graziani G. 2000. Clinical applications of telomerase in cancer treatment. Drug Resist Updates 3:161-170.
17. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857.
18. Galanis E, Buckner JC. 2000. Chemotherapy of brain tumors. Curr Opin Neurol 13:619-625.
19. Geenlee RT, Murray T, Bolden S, Wingo PA. 2000. Cancer statistics, 2000. CA Cancer J Clin 50:7-33.
20. Hirose Y, Berger MS, Pieper RO. 2001a. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963.
21. Hirose Y, Berger MS, Pieper RO. 2001b. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849.
22. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110-4118.
23. Hunting DJ, Gowans BJ, Henderson JF. 1985. Specificity of inhibitors of poly(ADP-ribose) synthesis: effects on nucleotide metabolism in cultured cells. Mol Pharmacol 28:200-206.
24. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. 1995. Histopathology, classification, and grading of gliomas. Glia 15:211-221.
25. Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, Kwong WK, Ho JW, Yuen ST. 1998. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 153:1181-1188.
26. Levin VA, Leibel SA, Gutin PH. 1999. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven. p 2022-2082.
27. Macdonald DR. 2001. Temozolomide for recurrent high-grade glioma. Semin Oncol 28(Suppl 13):3-12.
28. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP. 2000. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998-1007.
29. Milam KM, Thomas GH, Cleaver JE. 1986. Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res 165:260-268.
30. Moses K, Willmore E, Harris AL, Durkacz BW. 1990. Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide. Cancer Res 50:1992-1996.
31. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. 1997. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61.
32. Norton JC, Holt SE, Wright WE, Shay JW. 1998. Enhanced detection of human telomerase activity. DNA Cell Biol 17:217-219.
33. 6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60:5815-5824.
34. Osoba D, Brada M, Yung WK, Prados MD. 2000a. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36:1788-1795.
35. Osoba D, Brada M, Yung WK, Prados M. 2000b. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481-1491.
36. Paulsen F, Hoffmann W, Becker G, Belka C, Weinmann M, Classen J, Kortmann RD, Bamberg M. 1999. Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125:411-418.
37. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE, Shay JW. 1995. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17:1-15.
38. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
39. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58:1068-1073.
40. Sobrido MJ, Pereira CR, Barros F, Forteza J, Carracedo A, Lema M. 2000. Low frequency of replication errors in primary nervous system tumours. J Neurol Neurosurg Psychiatry 69:369-375.
41. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 9:1888-1895.
42. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E, Graziani G. 1998. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 285:884-893.
43. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, Bonmassar E, Graziani G. 1999. Treatment with temozolomide and poly(ADP-ribose) polymerase, inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13:901-909.
44. Tentori L, Portarena I, Bonmassar E, Graziani G. 2001a. Combined effects of adenovirus-mediated Wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ 8:457-469.
45. Tentori L, Portarena I, Vernole P, De Fabritiis P, Madaio R, Balduzzi A, Roy R, Bonmassar E, Graziani G. 2001b. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly-(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol 47:361-369.
46. Tentori L, Balduzzi A, Portarena I, Levati L, Vernole P, Gold B, Bonmassar E, Graziani G. 2001c. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ 8:817-828.
47. Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G. 2002a. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematological malignancy at the CNS site. Blood 99:2241-2244.
48. Tentori L, Portarena I, Vernole P, Gold B, Graziani G. 2002b. Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother Pharmacol 49:217-224.
49. Tentori L, Portarena I, Graziani G. 2002c. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 45:73-85.
50. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. 1994. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54:649-652.
51. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. 1999. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771.
52. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. 2000. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593.
53. 6-alkylguanine-DNA alkyltransferase assays. In: Brown R, Boeger-Brown U, editors. Cytotoxic drug resistance mechanisms. NJ: Humana Press. p 167.
54. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74:1030-1036.
55. Winter S, Weller M. 2000. Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. Eur J Pharmacol 398:177-183.
56. Zhu J, Guo SZ, Beggs AH, Maruyama T, Santarius T, Dashner K, Olsen N, Wu JK, Black P. 1996. Microsatellite instability analysis of primary human brain tumors. Oncogene 12:1417-1423.